Moreover, abnormal activation of FOXM1 also contributes to drug-resistance in cancers including ovarian cancer, breast cancer, prostate cancer, nasopharyngeal carcinoma, acute myeloid leukemia and colorectal cancer [36–41]. Here, FOXM1 is linked to colorectal cancer.